22 December 2015 – PLC wishes to congratulate Neurelis on their recent approval of Orphan Drug Designation for NRL-1. PLC has worked with Neurelis on the clinical and regulatory pathway of NRL-1 from its early stages and filed the Orphan Drug Designation application on behalf of Neurelis to the US FDA.

NEURELIS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR NRL-1 IN THE TREATMENT OF ACUTE REPETITIVE SEIZURES

https://neurelis.com/neurelis-news/fda-orphan-drug-designation